Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

Transgene Introduces Last Total Survival Information from Stage 2b TIME Test with TG4010 Immunotherapy in Non-Small Cell …

17:03 GMT

Transgene Introduces Last Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Offered at World Seminar on Lung Cancer Data confirm toughness of recently reported results Regulatory News: Transgene SA (Euronext: TNG) today announced the presentation1 by Dr. Elisabeth Quoix of final information from the Stage 2b component of the TIME … (continue reading)